Helmy Tarek, Patel Amar D, Alameddine Fadi, Wenger Nanette K
Grady Memorial Hospital, Atlanta, Georgia, USA.
MedGenMed. 2005 Oct 10;7(4):8.
During the past 3 years, the treatment of dyslipidemia has evolved significantly. The impact of recent trial data on management strategies in older patients is especially important, because the elderly segment of the US population continues to grow. Several clinical trials have been completed since the publication of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines were published in 2001. Recent trial data strongly support the use of lipid-lowering therapy in the elderly population. Although therapeutic lifestyle changes remain highly important, supplementation with lipid-lowering therapy has been shown to reduce the risk of cardiovascular events in both primary and secondary prevention models. Compelling data noted from recent clinical trials have prompted the NCEP to publish an updated report that addresses the significant interim developments.
在过去3年中,血脂异常的治疗有了显著进展。近期试验数据对老年患者管理策略的影响尤为重要,因为美国老年人口持续增长。自2001年美国国家胆固醇教育计划(NCEP)成人治疗专家组第三次报告发布以来,已完成了多项临床试验。近期试验数据有力支持在老年人群中使用降脂治疗。尽管治疗性生活方式改变仍然极为重要,但在一级和二级预防模式中,补充降脂治疗已被证明可降低心血管事件风险。近期临床试验得出的令人信服的数据促使NCEP发布了一份更新报告,阐述了重大的中期进展。